Financing the discovery of brand new plant-based drugs that could help
improve the lives of many people around the world.
Financing the discovery of brand new plant-based
Funding R&D companies to research the pharmacology of cannabinoids which continues to yield highly promising data and new IP across a range of therapeutic areas
Backing global-leading cannabinoid scientists which continue to explore the potential of a range of novel cannabinoid molecules in a number of distinct therapeutic areas including epilepsy, glioma, and schizophrenia
Managed by a team of proven entrepreneurs and businessmen that have a good understanding of this market
Medical cannabis is any cannabis-based medicine that relieves symptoms.
Cannabis has been used medicinally for more than 4,500 years.
In 2,727BC, Emperor Shen-Nung recognised its treatment properties in over 100 ailments including rheumatism and gout. Napoleon returned from Egypt in 1798 with cannabis which was investigated for pain relief and sedation. Elsewhere at that time, cannabis was being used to treat tumours, coughs and jaundice.
In the early 20th century cannabis use fell out of favour with
regulators and the culture of the western world.
Public opinion has firmly swung in favour of medical
cannabis which has put pressure on many governments
to legalise medical cannabis treatment
Trend led by Canada which changed it laws in 2001 to legalise the medicinal use of cannabis
Growing number of countries legalising cannabis for medical use
UK regulations changed in November 2018 following public pressure
Today the NHS prescribes medicinal cannabis for severe forms of epilepsy, nausea caused by chemotherapy and muscle stiffness/ spasms caused by MS
Medical cannabis is still in its introductory phase in the healthcare industry
Substantial growth is predicted for medical cannabis
Public opinion has firmly swung in favour of medical cannabis which has put
pressure on many governments to legalise medical cannabis treatment
| Company | Share price2 | Market capitalisation | Enterprise value | Comments |
|---|---|---|---|---|
| Canopy Growth (TSE:WEED) |
C$18.73 | £3,760m | £3,000m | First publicly-traded Canadian CBD company, and the first cannabis-producer to be listed on the NYSE in 2018. Multiple subsidiary companies and brands, including Tweed and Spectrum Therapeutics; with a product line the includes oils, concentrates, soft gel capsules and hemp. |
| GW Pharmaceuticals (NMQ:GWPH) |
US$81.80 | £2,060m | £1,590m | Global leader in developing cannabinoid-based medicines. Its Epidolex was the first FDA-approved medicine derived from cannabis plant, which it is focusing on turning into a block buster drug. |
| Aurora Cannabis (TSE:ACB) |
C$1.13 | £758m | £988m | Product line includes CBD oil, soft gels, and milled blends. Their CBD products are sold on a prescription, medical basis for Canadian markets. |
| Tilray (NSQ:TLRY) |
US$5.54 | £497m | £780m | First GMP-certified medical cannabis producer of cannabis flower and extract products; with its CBD products distributed to doctors, hospitals, governments, and researchers in five continents. |
| Charlotte’s Web (TSE:CWEB) |
C$5.68 | £344m | £316m | Charlotte’s Web has a unique formula to other CBD products, with a high amount of cannabidiol and low THC. Product lines includes CBD oil, gummies and capsules, as well as CBD dog products. |
| Medical Marijuana (OTC:MJNA) |
US$0.015 | £44m | £50m | Medical Marijuana developed the first legal supply of CBD and first publicly traded CBD company in the US. Has 8 brands of CBD products including CBD oils, hemp foods, clothing & baby products. |
| CV Sciences (OTC:CVSI) |
US$0.64 | £52m | £44m | Focuses on pharmaceutical and consumer markets. Developing cannabidiol-based medicine pending FDA approval. Sells various botanical-based CBD consumer products in health food stores. |
| Elixinol Global (ASX:EXL) |
A$0.275 | £18m | £10m | Wholesale CBD supplier of products such as oil capsules, tinctures, liposomes, topicals, and hemp seeds. Sold through dispensaries, shops, health stores, and through healthcare professionals. |
| Isodiol International (CBSX:ISOL) |
C$0.085 | £2.8m | £5.3m | Isodiolis a manufacturer of natural, non-GMO, THC-free cannabinoid products. Products include mainstream CBD products such as capsules, oral sprays, topicals, and oils. Sells its products in bulk material, private label, and wholesale options |
| Gaia Grow (CVE:GAIA) |
C$0.03 | £3.4m | £1.9m | Committed to creating sustainable and clean products has an extensive product line of natural remedies and supplements including hemp extract oils. |
Quickly being legalised in growing number of countries: Argentina, Brazil, Canada,
Chile, Colombia, Czech, Germany, Italy, Mexico, Spain, UK, USA and Uruguay.
Global medical cannabis market was
worth US$16.5 billion in 2019¹
22.8% compound annual growth rate (CAGR) forecast over the 2020-25 period¹
Market forecast to be worth
US$58.5 billion by 2025¹
Once you’ve finished all the research you will need to do, then you’ll be well ready
When writing essays, it is easy essay paper to become persistent.
for this kind of writing assignment.
More rapid growth is forecast for this sub-sector of the medical cannabis
Global CBD market valued at
US$553.7 million in 2020
by the end of 2026 growing at a CAGR
of 33.5% during 2021-26²
forecast to reach US$4,268.3 million
by the end of 2026
CBD wellness is an expanding category with CBD incorporated into edibles as well as being infused
into cosmetics and pet products. Industry clamouring for CBD to listed as “generally recognised as
safe” and so it is classified in the same way as vanilla flavouring and caffeine.
Multinational drinks brands have set their sights on developing cannabis based drinks. Owner of
Corona beer, Constellation brands, invested US$4 billion into the cannabis group Canopy Growth
in 2018. Coca-Cola is thought to have been in talks with Aurora Cannabis to create a CBD drink.
Speculation that Starbucks is becoming involved in this market.
In-depth market research to identify potential investee companies with compelling R&D in medical cannabis
Extensive face to face meetings with potential investee companies
Due diligence and painstaking analysis of technology and business model
Advance funds as direct investment or loans against achieving pre-agreed milestones
Work with management teams to create value
Appointment of key advisers and able to nominate a Non-Executive Director to the board
Exits will be sought by way of share buy-back, listing on a recognised stock exchange, acquisition by an industrial buyer, merger with another organisation etc.
Blackwell House
Guildhall Yard
London
EC2V 5AE
Tel: 020 3633 9145
Email: info@cannadex.com
